Drugs / Recombinant Vaccinia GM-CSF
Recombinant Vaccinia GM-CSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00625456 | Jun 2008 → Apr 2010 | head and neck squamous cell carcinoma, lung cancer, melanoma, renal cell carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Vaccinia GM-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00625456 ↗ |
| Known as | Pexa-Vec | “JX-594 (Pexa-Vec) administered by intratumoral injection in patients with metastatic disease to the liver” NCT00625456 ↗ |
| Known as | RAC VAC GM-CSF | “Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)” NCT00625456 ↗ |
| Route | Intravenous | “Intravenous infusion is administered once over a 60 minute period” NCT00625456 ↗ |